X1-203
You can schedule a meeting with us through the ISPOR virtual platform here (opens on November 1st).
Session Title: How AI Unlocks RWE in Belgium, France, Germany – Use Case in Rare Diseases (hATTR and ATTR-CM)
Date/Time: Tuesday, 8 November 2022 from 11:40-12:00
Location: Austria Center Vienna, HEOR Theater 2, Hall X1
Presentation description
Multi-center RWE Hubs are enabling large-scale evidence generation across various therapeutic areas (i.e. cardio, onco, neuro) in Belgium, France, and Germany. Georges De Feu (LynxCare) and Jean-Baptiste Angeloglou (PSIH) will share how these federated clinical data networks create value for patients, clinicians, and researchers. Clara Oeste (LynxCare) will showcase how these insights are being used to identify patients at-risk of rare diseases through A.I. and NLP. LynxCare works with leading hospitals in Europe and the United States, and facilitates scientific research for Life Sciences companies such as AstraZeneca, Pfizer and Novartis within a strict ethical and legal framework.
About Georges De Feu (CEO & Co-Founder, LynxCare)
Georges De Feu is a 3x successful start/scale-up founder & exec in HealthTech. Georges is the CEO and founder of LynxCare, the Big Data market leader in healthcare. With an AI-driven data platform, they help hospitals unlock previously unavailable clinical data for better patient care and scientific research. They work with leading hospitals in Europe and the United States, and facilitate scientific research for Life Sciences companies such as AstraZeneca, Pfizer and Novartis within a strict ethical and legal framework.
About Clara Oeste (Senior Medical Writer, LynxCare)
Clara L. Oeste obtained her BSc and MSc in Biochemistry and Molecular Biology at the Complutense University in Madrid, Spain. Her PhD at the Spanish National Research Council focused on the dynamics of RAS proteins, and during her 5+ years as a postdoc, she focused on their role in leukaemia and breast cancer. She has co-authored numerous scientific papers, editorials, and book chapters. Recently, as a medical writer and scientific advisor, she has focused on the value of real-world evidence (RWE) in diverse therapeutic areas to foster AI-driven clinical insights and patient outcomes research.
About Jean-Baptiste Angeloglou (Managing Director, PSIH Group)
Jean-Baptiste Angeloglou is the Managing Director of PSIH Group, the leader in Business Intelligence in hospitals in France. After obtaining his MSc in Law and Taxation from the Panthéon-Assas University in Paris, France, he held positions as Deputy Managing Director at CEGEDIM, Head of Sales at CMPMedica, and Commercial Director and member of the ComEx of IQVIA France. PSIH has been supporting healthcare organisations for over 20 years in analyzing their structured data and is active in more than 1,000 hospitals. PSIH also manages databases such as the French hospital discharge database (PMSI) and French nation-wide healthcare data system (SNDS), which is the largest RWD source in Europe.
Health data is siloed in different languages and software systems. Using AI and NLP, LynxCare unlocks structured and unstructured clinical data and creates federated clinical data warehouses.
In line with the recently announced European Health Data Space, LynxCare utilises the OMOP Common Data Model.